INmune Bio (NASDAQ:INMB – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.
Volatility and Risk
INmune Bio has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
Institutional and Insider Ownership
12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations for INmune Bio and NewAmsterdam Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INmune Bio | 1 | 0 | 0 | 1 | 2.50 |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
NewAmsterdam Pharma has a consensus price target of $48.90, indicating a potential upside of 138.56%. Given NewAmsterdam Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than INmune Bio.
Valuation & Earnings
This table compares INmune Bio and NewAmsterdam Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INmune Bio | $50,000.00 | 832.50 | -$45.93 million | ($0.67) | -2.24 |
| NewAmsterdam Pharma | $22.50 million | 108.90 | -$203.82 million | ($2.16) | -9.49 |
INmune Bio has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares INmune Bio and NewAmsterdam Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| INmune Bio | N/A | -82.87% | -62.23% |
| NewAmsterdam Pharma | -3,644.21% | -34.81% | -31.50% |
About INmune Bio
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
